
Curriculum Vitae

Paris P. Bransford, M.D.

Present Position:

Southeast Texas Cardiology Associates II, L.L.P.

2693 North Street

Beaumont, Texas 77702

(409) 832-8862 (409) 835-5132 Fax

Southeast Texas Clinical Research Center

2680 McFaddin Avenue

Beaumont, Texas 77702

(409) 839-4003 (409) 839-8469 fax

EDUCATION

- 7/94-6/95 Georgetown University Hospital, Washington, D.C.
Electrophysiology Fellowship
- 1/94-6/95 Veterans Affairs Hospital, Washington, D.C.
Research Assistant in the Lab of Janice Jones, Ph.D.
- 7/93-12/93 Georgetown University Hospital, Washington, D.C.
Medicine Residency
- 7/90-6/93 Georgetown University Hospital, Washington, D.C.
Cardiology Fellowship
- 1/88-6/88 Veterans Administration Hospital, Washington, D.C.
Medicine Internship
- 7/88-6/90 Medicine Residency
- 7/87-12/87 Howard University Hospital, Washington, D.C.
Surgery Internship
- 7/83-6/87 University of Texas Medical Branch, Galveston, Texas
- 9/79-12/82 Vanderbilt University, Nashville, TN
Bachelor of Science – Cum Laude Graduate
Major: Biology - Minor: Chemistry

AWARDS & HONORS

- | | |
|------|---|
| 1992 | Mamie Doud Eisenhower Award, American Heart Association
\$18,000.00 Fellowship for research support(12 months) |
| 1987 | Herman A. Barnett Award of Surgery and Anesthesia, UTMB |
| 1999 | Memorial Hermann Baptist Healthcare System
Doctor of the Year |

PUBLICATIONS

Manuscripts

Correlations Between Shock Induced Response Duration And Success of Defibrillation. Oscar H. Tovar, M.D., Paris P. Bransford, M.D., Jean B. Moubarak, M.D., Kevin B. Milne M.S.E.E., Ashwin E. Amanna M.S.E.E., and Janice L. Jones, Ph.D. *Proc IEEE Eng Med Biol Soc* 1994;15.

Probability of Induction and Stabilization of Ventricular Fibrillation with Epinephrine. Tovar O, Bransford PP, Jones JL. *J Mol Cell Cardiol* 1998;30:373-382.

Abstracts

Epinephrine Reduces Ventricular Fibrillation Threshold and Stabilizes Fibrillation by Reducing Cellular Refractory Period During Fibrillation. Paris P. Bransford, P. Jacob Varghese, Oscar H. Tovar, Kevin B. Milne, Janice L. Jones. *Pacing Clin Electrophysiol* 1993;16:866

Epinephrine Facilitates Fibrillation by Shortening Action Potential Duration and Refractory Period at VT/Fibrillation Cycle Lengths. Oscar H. Tovar, Kevin B. Milne, Paris P. Bransford, P. Jacob Varghese, Ronald E. Jones, Janice L. Jones. *Pacing Clin Electrophysiol* 1993;16:866

Mechanisms of Spontaneous Defibrillation in the Rabbit Heart. P. Jacob Varghese, Paris P. Bransford, Oscar H. Tovar, Kevin B. Milne, Janice L. Jones. *JACC* 1993;21 (2) 306A.

Recording with Single Optical Fiber Systems and Cooled CCD Imager. V.Krauthamer, Ph.D; J.L. Jones, Ph.D; O. Tovar, M.D.; P. Bransford, M.D.; A.E. Amanna, B.S.; C.C. Davis, Ph.D.
Proc. AAMI/NHLBI Cardiovascular Science and Technology Section 12/1993; pg. 39

Shock Induced Response Duration and Type of Successful Defibrillation. Tovar O, Bransford P.P., Moubarak, J.B., Milne K.B., Amanna A.E., Jones J.L. Abstract. Presented at American Heart Association Meeting, November 1994.

Extension of Refractoriness and Probability of Successful Defibrillation. Tovar O, Moubarak J.B., Bransford P.P., Milne K.B., Amanna A.E., Jones J.L. Abstract. Presented at American Heart Association Meeting, November 1994.

PROFESSIONAL SOCIETIES

Association of Black Cardiologists
American College of Cardiology, Associate Fellow
American Heart Association
American Medical Association
Jefferson County Medical Society
North American Society of Pacing and Electrophysiology

LECTURES

2/1991	Pathophysiology and treatment of cardiomyopathy
3/1992	History and theory of electric counter shock
8/1992	Basic mechanisms of epinephrine's effect on the monophasic action potential
9/1996	Mechanisms and treatment of SVT

- 10/1996 Introducing to ECG analysis
- 3/1997 Electrocardiographic analysis of acute myocardial infarction
- 4/1997 Treatment of Ventricular Tachycardia
- 3/1999 Use of IV Amiodarone for Ventricular Tachycardia
(Beaumont and Tyler, Texas)
- 7/1999 Symposium on Supraventricular Tachycardia Mechanisms and
Treatment included intracardiac electrograms and pharmacology
- 9/1999 Diagnosis and Management of SVT (St. Elizabeth Hospital)

PRESENTATIONS

- 5/1993 North American Society of Pacing and Electrophysiology,
Abstract Presentation

CLINICAL EXPERIENCE

- 8/95-8/97 The Heart Center of East Alabama, Opelika, AL.
Cardiac Electrophysiology
- 10/97-Present Southeast Texas Cardiology Associates, Beaumont, Texas.
Cardiac Electrophysiology

CERTIFICATIONS

- 1994 ABIM, Internal Medicine, Board Certified
- 1997 ABIM, Cardiovascular Diseases, Board Certified
- 1998 ABIM, Clinical Cardiac Electrophysiology, Board Certified

CLINICAL INTERESTS

Implantation of Brady pacing devices
Implantation of implantable cardiac defibrillators
Ablation of supraventricular tachycardia
Diagnostic electrophysiology studies
Cardiac mapping
Tilt table studies
Temporary pacing
Diagnostic coronary angiography
Diagnostic left heart catheterization
Diagnostic right heart catheterization
Transseptal puncture to left atrium with/without TEE guidance
(for left-sided pathways)

CLINICAL RESEARCH

5/1/2002 - 2005	Pfizer - Lipitor/ Norvasc Protocol # A3841012 Gemini Study – Sub-Investigator
8/2002 – 2005	Aventis – Acute Coronary Syndrome Study Protocol XRP4563B/4001 Rescue ACS Study – Principal Investigator
12/2003 – 12/2006	Otsuka Maryland Research Institute Protocol 156-03-236 Acute Decompensated – CHF Study Sub-Investigator
12/2004 – 2006	Guidant CRT Renewal Registry Principal Investigator
1/2006 –	St. Jude Medical ACT Registry ICD Registry
1/2006 –	St. Jude Medical PAS Registry Device Performance Registry

CLINICAL RESEARCH CONTINUED

12/2006 – 5/2009	Reliant Pharmaceuticals – Omacor Protocol OM8 afib Recurrent, Symptomatic atrial fibrillation
9/2006-9/2007	Pfizer – Caduet Protocol A3841046 HTN and Hyperlipidemia Sub-Investigator
7/2004-12/2006	Pfizer – torceptrapib / atorvastatin Protocol A5091043 Hypercholesterolemia and CV events Sub-Investigator
12/2005-9/2007	AstraZeneca – Rosuvastatin / Atorvastatin Protocol 4522US/001 ACS Sub-Investigator
8/2006 – 4/2009	Amgen, Inc. – Darbepoetin Alfa Protocol 20050222 Heart Failure and Anemia Sub-Investigator
10/2005 – 2007	Lilly – Prasugrel and ASA vs. Clopidogrel and ASA Protocol H7T-MC-TAAL ACS Sub-Investigator
2/2006 – 6/2009	Amgen, Inc. – Darbepoetin Alfa Protocol 20010184 Diabetes, CKD, and anemia Sub-Investigator
6/2006 – 12/2006	Palatin Technologies – PT-141 Protocol PT-141-2006-32 HTN safety for ED drug Sub-Investigator
8/2006 – 6/2008	Novartis – Diovan and Lotrel Protocol CVAL483AUS62 Observational Study for BP Sub-Investigator
2006 – Present	Johnson & Johnson – Rivaroxiban and Coumadin Protocol 9039039 AFL3001 Atrial Fibrillation Sub-Investigator.

CLINICAL RESEARCH CONTINUED

12/2006 – Present	Pfizer – Celebrex, Naproxen and Aleve Protocol A3191172 Osteoarthritis and Rheumatoid Arthritis Sub-Investigator
2006 – 6/2009	Reliant – Omacor Protocol OM8 Atrial Fibrillation Primary Investigator
2006 – 6/2009	Gilead – Darusentan and Guanfacine Protocol DAR312 Resistant Hypertension Sub-Investigator
3/2007 – 12/2008	Merck – Exetimibe and Atorvastatin Protocol 112-01 Hypercholesterolemia Sub-Investigator
5/2008 – 01/2009	Cogentus – Clopidogrel and CGT-2168 Protocol CG104 Reduce GI Events and Bleeding Sub-Investigator
11/2008 – 6/2009	Bristol Myers Squibb/ Pfizer – Apixiban Protocol CV185057 Deep Vein Thrombosis and Pulmonary Embolism Sub-Investigator
02/2009 – 2009	Roche – dalcetapib Protocol NC20971C Hypercholesterolemia Sub-Investigator
04/2010 -	Novartis – enalapril – ACE /NEP Inhibitor Protocol CLCZ696B2314 Chronic heart failure and reduced EF. Sub-Investigator
03/2010 -	Pozen – ASA /omeprazole Protocol PA32540-302 Incidence of Gastric Ulcers Sub-Investigator

07/2010 -	Ortho-McNeil Janssen RIVAROX-AFL-4001 Atrial Fibrillation Observational Registry Sub-Investigator
04/2011	Novartis – Aliskiren / Valsartan Protocol CSPV100AUS02 Hypertension / Type 2 Diabetes Principal Investigator
04/2011	Novartis – canakinumab Protocol CACZ885M2301 Post Myocardial Infarction / elevated hsCRP Sub-Investigator
11/2011	Principal Investigator Boston Scientific Multi-SENSE Device Trial
05/2012	Amarin Reduce-It Trial Sub-Investigator
08/2012	Boehringer Ingleheim GLORIA-AF New Onset Atrial Fibrillation Registry Sub-Investigator
08/2012	Astra Zeneca Ethnicity Study Stable CAD Sub-Investigator
08/2012	Takeda EXAMINE Aldogliptin Sub-Investigator
08/2012	DCRI / NIH BRIDGE study Principal Investigator
8/2013	Boston Scientific LSS of 4-SITE Principal Investigator
11/2013	Sub- Investigator Novartis – enalapril – ACE /NEP Inhibitor Protocol CLCZ696B2228 TITRATION Trial

2/2014-Present	Sub-Investigator NHLBI CIRT Trial
4/2014-Present	Principal Investigator Boston Scientific NAVIGATE X4
4/2014	Principal Investigator ARCA Biopharma GENETIC-AF
6/2014	Principal Investigator Sanofi Multaq Chart Review
7/2014- Present	Sub-Investigator Novartis – enalapril – ACE /NEP Inhibitor Protocol CLCZ696D2301 PARAGON
8/2014 - Present	Sub-Investigator Pfizer / BMS Protocol B0661025 / CB185-267 EMANATE
06/2013 - Present	Sub- Investigator Ortho-McNeil Janssen RIVAROX-AFL-4002 ORBIT II - Atrial Fibrillation Observational Registry SATELLITE – Substudy 2015
06/2015 – Present	Sub- Investigator AstraZeneca D513BC00001 THEMIS
08/2015 – Present	Sub- Investigator Regeneron / DCRI PALM REGISTRY
08/2015 – Present	Sub- Investigator Pfizer B1481022 SPIRE 1 – Hyperlipidemia
08/2015 – Present	Sub- Investigator Pfizer B1481038 SPIRE 2 – Hyperlipidemia

01/2016 – Present Sub- Investigator
Novartis
CLCZ696BUS02
CHAMP-HF

LICENSURE

Texas (H5423)

AFFILIATIONS

Memorial Hermann Baptist Hospital - Hospital Privileges
3080 College Street
Beaumont, Texas 77701

BIOGRAPHY

Place of Birth Nashville, TN
Date of Birth May 1, 1961
Marital Status Married
Children Three